Picozzi, V. J., Ramanathan, R. K., Lowery, M. A., Ocean, A. J., Mitchell, E. P., O’Neil, B. H., … Goldenberg, D. M. (2014). Feasibility and results of a randomized phase Ιb study of fractionated ⁹⁰Υ-clivatuzumab tetraxetan in patients with metastatic pancreatic cancer having two or more prior therapies. In Journal of Clinical Oncology (Vol. 32, pp. 4026–4026). American Society of Clinical Oncology (ASCO). https://doi.org/10.1200/jco.2014.32.15_suppl.4026

Picozzi, Vincent J., Ramesh K. Ramanathan, Maeve Aine Lowery, Allyson J. Ocean, Edith P. Mitchell, Bert H. O’Neil, Michael J. Guarino, et al. “Feasibility and results of a randomized phase Ιb study of fractionated ⁹⁰Υ-clivatuzumab tetraxetan in patients with metastatic pancreatic cancer having two or more prior therapies.” In Journal of Clinical Oncology, 32:4026–4026. American Society of Clinical Oncology (ASCO), 2014. https://doi.org/10.1200/jco.2014.32.15_suppl.4026.

Picozzi VJ, Ramanathan RK, Lowery MA, Ocean AJ, Mitchell EP, O’Neil BH, et al. Feasibility and results of a randomized phase Ιb study of fractionated ⁹⁰Υ-clivatuzumab tetraxetan in patients with metastatic pancreatic cancer having two or more prior therapies. In: Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2014. p. 4026–4026.

Picozzi, Vincent J., et al. “Feasibility and results of a randomized phase Ιb study of fractionated ⁹⁰Υ-clivatuzumab tetraxetan in patients with metastatic pancreatic cancer having two or more prior therapies.” Journal of Clinical Oncology, vol. 32, no. 15_suppl, American Society of Clinical Oncology (ASCO), 2014, pp. 4026–4026. Crossref, doi:10.1200/jco.2014.32.15_suppl.4026.

Picozzi VJ, Ramanathan RK, Lowery MA, Ocean AJ, Mitchell EP, O’Neil BH, Guarino MJ, Conkling PR, Cohen SJ, Bahary N, Frank RC, Dragovich T, Bridges BB, Braiteh FS, Lee F-C, Gribbin TE, Richards DA, Starodub A, Wegener WA, Goldenberg DM. Feasibility and results of a randomized phase Ιb study of fractionated ⁹⁰Υ-clivatuzumab tetraxetan in patients with metastatic pancreatic cancer having two or more prior therapies. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2014. p. 4026–4026.